Moore, PS, Chang, Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nature Reviews Cancer
2010; 10: 878–889.
Bian, T, et al.
Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice. Molecular Cancer Therapeutics
2008; 7: 1329–1335.
Dillner, J. Prevention of human papillomavirus-associated cancers. Seminars in Oncology
2015; 42: 272–283.
Winer, RL, et al.
Condom use and the risk of genital human papillomavirus infection in young women. New England Journal of Medcine
2006; 354: 2645–2654.
Chaturvedi, AK, et al.
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. Journal of Clinical Oncology
2011; 29: 4294–42301.
Saraiya, M, et al.
US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. Journal of the National Cancer Institute
2015; 107: djv086.
Steenbergen, RD, et al.
Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nature Reviews Cancer
2014; 14: 395–405.
Johansson, C, Schwartz, S. Regulation of human papillomavirus gene expression by splicing and polyadenylation. Nature Reviews Microbiology
2013; 11: 239–251.
Abbate, EA, Voitenleitner, C, Botchan, MR. Structure of the papillomavirus DNA-tethering complex E2: Brd4 and a peptide that ablates HPV chromosomal association. Molecular Cell
2006; 24: 877–889.
Ghittoni, R, et al.
Role of human papillomaviruses in carcinogenesis. Ecancermedicalscience
2015; 9: 526.
Muñoz, N, et al.
Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine
2003; 348: 518–527.
Szarewski, A, et al.
Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. Journal of Clinical Microbiology
2012; 50: 1867–1873.
Eide, ML, Debaque, H. HPV detection methods and genotyping techniques in screening for cervical cancer. Annales De Pathologie
2012; 32: e15–23, 401–409.
Lacey, CJ, Lowndes, CM, Shah, KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine
2006; 24: S35–41.
Elrefaey, S, et al.
HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorinorhinolaryngologica Italica
2014; 34: 299–309.
Kreimer, AR, et al.
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiology, Biomarkers & Prevention
2005; 14: 467–75.
Muñoz, N, et al.
Chapter 1: HPV in the etiology of human cancer. Vaccine
2006; 24 Suppl 3: S3/1–10.
Barcelos, AC, et al.
Atypical squamous cells of undetermined significance: Bethesda classification and association with human papillomavirus. Infectious Diseases in Obstetrics and Gynecology
2011; 2011: 904674.
Sun, B, et al.
Prevalence and genotype distribution of human papillomavirus infection in Harbin, Northeast China. Archives of Virology
2014; 159: 1027–1032.
Hong, H, et al. Prevalence and genotype distribution of HPV infection among women in Ningbo, China. International Journal of Gynecology & Obstetrics
2015; 131: 96–99.
Zhi, YF, et al.
Prevalence and genotype distribution of human papillomavirus in women in the Henan Province. Genetics and Molecular Research
2015; 14: 5452–5461.
Xue, H, et al.
Prevalence and genotype distribution of human papillomavirus infection in asymptomatic women in Liaoning province, China. Journal of Medical Virology
2015; 87: 1248–1253.
Bi, Q, et al.
Human papillomavirus prevalence and genotypes distribution among female outpatients in Qingdao, East China. Journal of Medical Virology. Published online: 9 June 2015. doi:10.1002/jmv.24281.
Clifford, GM, et al.
Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiology, Biomarkers & Prevention
2005; 14: 1157–1164.
Bhatla, N, et al.
A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination. Vaccine
2008; 26: 2811–7.
Anderson, L, et al.
Prevalence of human papillomavirus in women attending cervical screening in the UK and Ireland: new data from Northern Ireland and a systematic review and meta-analysis. Journal of Medical Virology
2013; 85: 295–308.
Wheeler, CM, et al.
Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. Journal of the National Cancer Institute
2009; 101: 475–487.
de Sanjosé, S, et al.
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infectious Diseases
2007; 7: 453–459.
Chew, GK, et al.
Human papillomavirus 16 infection in adenocarcinoma of the cervix. British Journal of Cancer
2005; 93: 1301–1304.
Stokley, S, et al.
Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014–United States. Morbidity and Mortality Weekly Report
2014; 63: 620–4.
CDC. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report
2010; 59: 626–629.